Company news
Tempus AI, Inc. news in 2024
Tempus AI, Inc.'s news releases, calls and decks from 2024, newest first.
Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions
December 17, 2024
New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus ECG-AF Device
December 16, 2024
Personalis and Tempus Expand Collaboration to Biopharma
December 15, 2024
Tempus to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 24, 2024
Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®
November 11, 2024
Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
November 10, 2024
Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting
November 7, 2024
Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test
November 6, 2024
Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics
November 3, 2024
Tempus to Report Third Quarter 2024 Financial Results on November 4
November 2, 2024
Tempus to Report Third Quarter 2024 Financial Results on November 7
October 23, 2024
Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
September 25, 2024
Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024
September 12, 2024
Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients
September 11, 2024
Tempus Announces Real World Data Collaboration with BioNTech
September 3, 2024
Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 27, 2024
Personalis and Tempus Announce Expanded Collaboration
August 15, 2024
NPJ Precision Oncology Publishes Tempus Study on Validation of its HLA-LOH Investigational Assay
August 7, 2024
Tempus Reports Second Quarter 2024 Results
August 5, 2024
Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2
July 31, 2024
Tempus Announces Expanded Data and Sequencing Collaboration with Remix Therapeutics
July 29, 2024
GeneCentric Therapeutics Announces American Medical Association Has Granted a PLA Code for PurIST Pancreatic Cancer Test
July 23, 2024
Tempus to Report Second Quarter 2024 Financial Results on August 6
July 16, 2024
Tempus Expands Immuno-Oncology Portfolio with Launch of AI-enabled, Multimodal Immune Profile Algorithmic Tests
July 15, 2024
Tempus Surpasses 500 Research Publications
July 9, 2024
American Medical Association Grants PLA Code to Tempus Algorithmic Test, PurISTSM
July 7, 2024
CMS Awards Tempus With Advanced Diagnostic Laboratory Test (ADLT) Status for its xT CDx Test
July 1, 2024
Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib
June 25, 2024
Tempus Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension
June 24, 2024
Tempus Announces Pricing of Initial Public Offering
June 12, 2024
Calls in 2024
Decks in 2024
- Technical Presentation (November 2024)
Technical · 13 slides · November 2024